How Quickly Does Ebglyss Start Working for Atopic Dermatitis?
Ebglyss (lebrikizumab-lbkz), approved by the FDA in September 2024 for moderate-to-severe atopic dermatitis in adults and children 12+ weighing at least 40 kg, shows noticeable improvements within 2 weeks of the first subcutaneous dose. In pivotal trials (ADvocate1, ADvocate2, ADjoin), 25-43% of patients achieved clear or almost clear skin (IGA 0/1) by week 16, with itch reduction starting as early as week 1-2 based on patient-reported outcomes. Full efficacy plateaus around weeks 16-36, with maintenance dosing every 2 weeks after initial loading doses at weeks 0, 2, and optional week 4.[1][2]
What Do Patients Notice First—Itch Relief or Skin Clearing?
Itch reduction often precedes visible skin changes. In trials, Ebglyss improved pruritus scores by week 2 (e.g., 40-50% reduction in weekly severity), driven by its targeted IL-13 blockade, which disrupts the itch-scratch cycle faster than some broader immunosuppressants. Skin clearance (EASI-75 score) follows, with 30-60% of patients hitting 75% improvement by week 16 versus 10-20% on placebo.[1][3]
How Long Until Full Results, and What's the Dosing Schedule?
Initial response: 1-4 weeks for symptom relief.
Optimal response: 16 weeks for most (60-70% achieve EASI-75).
Maintenance: Every 2 weeks indefinitely if effective; some switch to every 4 weeks after 16 weeks.
Non-responders may see no benefit by week 16, prompting discontinuation.[2][4]
Why Might It Take Longer for Some Patients?
Factors include baseline severity, prior treatments (e.g., slower in Dupixent failures), body weight, and adherence. Trial data showed 20-30% slower response in severe cases (IGA 4). Concomitant topicals sped up results by 1-2 weeks. No data yet on real-world variability post-approval.[1][3]
How Does Ebglyss Compare to Dupixent in Speed of Onset?
| Aspect | Ebglyss | Dupixent (dupilumab) |
|--------|---------|----------------------|
| Itch relief onset | Week 1-2 | Week 1-4 |
| EASI-75 by week 16 | 43-60% | 36-51% |
| Dosing frequency | Q2W after loading | Q2-4W |
| Mechanism | IL-13 specific | IL-4/IL-13 dual |
Ebglyss matches or edges Dupixent in itch speed due to selective IL-13 targeting but lacks head-to-head trials.[1][5]
When Can You Expect Results if You're Switching Treatments?
Washout from prior biologics (e.g., 4-8 weeks for Dupixent) delays start, but Ebglyss trials included switchers with response by week 4-16. Monitor IGA/EASI at week 16 per label.[2][4]
Sources:
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfdadocs/label/2024/761351s000lbl.pdf
[2] NEJM ADvocate Trials: https://www.nejm.org/doi/full/10.1056/NEJMoa2308387
[3] Lancet ADjoin Study: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00763-5/fulltext
[4] Eli Lilly Prescribing Info: https://pi.lilly.com/us/ebglyss-uspi.pdf
[5] Dupixent Label: https://www.regeneron.com/downloads/dupixentfpi.pdf